MedTrace Logo

Study to Evaluate the Safety and Efficacy of ASC40 in Subjects With Moderate to Severe Acne Vulgaris

NCT05104125 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 180

Last updated 2025-05-16

No results posted yet for this study

Summary

This is a phase2, randomized, double-blind, multi-center, multi-dose and placebo parallel controlled design. The subjects in the study group were given double-blind drugs, and they were taken (orally) after dinner every day according to the requirements of clinical trial scheme.

Conditions

  • Acne Vulgaris

Interventions

DRUG

ASC40 25mg

25mg of ASC40 orally once daily for 12 weeks.

DRUG

ASC40 50mg

50mg of ASC40 orally once daily for 12 weeks.

DRUG

ASC40 75mg

75mg of ASC40 orally once daily for 12 weeks.

DRUG

Placebo

Placebo orally once daily for 12 weeks.

Sponsors & Collaborators

  • Ascletis Pharmaceuticals Co., Ltd.

    lead INDUSTRY

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
40 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2022-01-12
Primary Completion
2023-04-10
Completion
2023-04-10

Countries

  • China

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05104125 on ClinicalTrials.gov